Eirgen Drug Patent Portfolio
Eirgen owns 1 orange book drug protected by 17 US patents Given below is the list of Eirgen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10300078 | Stabilized modified release vitamin D formulation and method of administering same | 14 Mar, 2034 | Active |
| US10357502 | Stabilized modified release vitamin D formulation and method of administering same | 14 Mar, 2034 | Active |
| US11253528 | Stabilized modified release Vitamin D formulation and method of administering same | 14 Mar, 2034 | Active |
| US9861644 | Stabilized modified release vitamin D formulation and method of administering same | 14 Mar, 2034 | Active |
| US11801253 | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease | 07 Sep, 2030 | Active |
| US8426391 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | 27 Aug, 2028 | Active |
| US8361488 | Methods and compositions for controlled release oral dosage of a vitamin D compound | 19 Jul, 2028 | Active |
| US11154509 | Methods for controlled release oral dosage of a vitamin D compound | 25 Apr, 2028 | Active |
| US8207149 | Method for treating secondary hyperparathyroidism in CKD | 25 Apr, 2028 | Active |
| US8778373 | Methods for controlled release oral dosage of a vitamin D compound | 25 Apr, 2028 | Active |
| US9408858 | Method for treating secondary hyperparathyroidism in CKD | 25 Apr, 2028 | Active |
| US9498486 | Method for controlled release oral dosage of a vitamin D compound | 25 Apr, 2028 | Active |
| US9925147 | Method for treating secondary hyperparathyroidism in CKD | 25 Apr, 2028 | Active |
| US10213442 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | 02 Feb, 2027 | Active |
| US8906410 | Oral dosage form of 25-hydroxyvitamin D | 02 Feb, 2027 | Active |
| US9943530 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | 02 Feb, 2027 | Active |
| US6582727 | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same | 22 Aug, 2020 | Expired |
Latest Legal Activities on Eirgen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eirgen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9498486 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2024 | US9408858 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2023 | US8207149 |
| Mail Patent eGrant Notification | 31 Oct, 2023 | US11801253 |
|
Recordation of Patent Grant Mailed
Critical
| 31 Oct, 2023 | US11801253 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 31 Oct, 2023 | US11801253 |
| Patent eGrant Notification | 31 Oct, 2023 | US11801253 |
| Recordation of Patent eGrant | 31 Oct, 2023 | US11801253 |
|
Email Notification
Critical
| 31 Oct, 2023 | US11801253 |
|
Email Notification
Critical
| 12 Oct, 2023 | US11801253 |
|
Issue Notification Mailed
Critical
| 11 Oct, 2023 | US11801253 |
|
Application Is Considered Ready for Issue
Critical
| 02 Oct, 2023 | US11801253 |
| Dispatch to FDC | 02 Oct, 2023 | US11801253 |
|
Issue Fee Payment Received
Critical
| 27 Sep, 2023 | US11801253 |
|
Issue Fee Payment Verified
Critical
| 27 Sep, 2023 | US11801253 |
Eirgen Drug Patents' Oppositions Filed in EPO
Eirgen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 21, 2021, by Dsm Nutritional Products Ag. This opposition was filed on patent number EP14717038A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16164563A | Aug, 2022 | DSM Nutritional Products Ltd | Granted and Under Opposition |
| EP19217651A | Feb, 2022 | DSM Nutritional Products AG | Granted and Under Opposition |
| EP18155036A | May, 2021 | DSM Nutritional Products AG | Granted and Under Opposition |
| EP14717038A | Apr, 2021 | DSM Nutritional Products AG | Granted and Under Opposition |
Eirgen's Family Patents
Eirgen drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 17.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Eirgen Drug List
Given below is the complete list of Eirgen's drugs and the patents protecting them.
1. Rayaldee
Rayaldee is protected by 17 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10300078 | Stabilized modified release vitamin D formulation and method of administering same |
14 Mar, 2034
(8 years from now)
| Active |
| US10357502 | Stabilized modified release vitamin D formulation and method of administering same |
14 Mar, 2034
(8 years from now)
| Active |
| US11253528 | Stabilized modified release Vitamin D formulation and method of administering same |
14 Mar, 2034
(8 years from now)
| Active |
| US9861644 | Stabilized modified release vitamin D formulation and method of administering same |
14 Mar, 2034
(8 years from now)
| Active |
| US11801253 | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
07 Sep, 2030
(5 years from now)
| Active |
| US8426391 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
27 Aug, 2028
(3 years from now)
| Active |
| US8361488 | Methods and compositions for controlled release oral dosage of a vitamin D compound |
19 Jul, 2028
(3 years from now)
| Active |
| US11154509 | Methods for controlled release oral dosage of a vitamin D compound |
25 Apr, 2028
(2 years from now)
| Active |
| US8207149 | Method for treating secondary hyperparathyroidism in CKD |
25 Apr, 2028
(2 years from now)
| Active |
| US8778373 | Methods for controlled release oral dosage of a vitamin D compound |
25 Apr, 2028
(2 years from now)
| Active |
| US9408858 | Method for treating secondary hyperparathyroidism in CKD |
25 Apr, 2028
(2 years from now)
| Active |
| US9498486 | Method for controlled release oral dosage of a vitamin D compound |
25 Apr, 2028
(2 years from now)
| Active |
| US9925147 | Method for treating secondary hyperparathyroidism in CKD |
25 Apr, 2028
(2 years from now)
| Active |
| US10213442 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| US8906410 | Oral dosage form of 25-hydroxyvitamin D |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| US9943530 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| US6582727 | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
22 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rayaldee's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List